(Q41735644)

8 October 2017

1 reference

title

Perspectives in antisense therapeutics (English)

1 reference

8 October 2017

Agrawal S

1

1 reference

8 October 2017

Iyer RP

series ordinal

2

1 reference

8 October 2017

publication date

1 October 1997

1 reference

Pharmacology & Therapeutics

8 October 2017

published in

1 reference

8 October 2017

volume

76

1 reference

8 October 2017

issue

1-3

1 reference

8 October 2017

page(s)

151-160

1 reference

Antisense oligonucleotides: towards clinical trials

8 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Modified oligonucleotides as therapeutic and diagnostic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Pharmacokinetics of antisense oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Novel enzymatic and immunological responses to oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Specific regulation of gene expression by antisense, sense and antigene nucleic acids

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Transport of phosphorothioate oligonucleotides in kidney: Implications for molecular therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Renal disposition characteristics of oligonucleotides modified at terminal linkages in the perfused rat kidney.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Effect of RNA secondary structure and modified bases on the inhibition of trypanosomatid protein synthesis in cell free extracts by antisense oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects*

1 reference

https://api.crossref.org/works/10.1016%2FS0163-7258%2897%2900108-3

7 January 2021

10.1016/S0163-7258(97)00108-3

Identifiers

DOI

1 reference

8 October 2017

1 reference